Latest stock market news videos & Morning Bell

In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US.